Table 1.
Updated TEAEs (frequency ≥ 15%) for patients with MCL (n = 16).
| AE, n (%) | Grade 1–2 | Grade ≥ 3 | Total |
|---|---|---|---|
| Cough | 7 (44) | 0 | 7 (44) |
| Diarrhea | 7 (44) | 0 | 7 (44) |
| Thrombocytopenia | 4 (25) | 3 (19) | 7 (44) |
| Contusion | 5 (31) | 0 | 5 (31) |
| Nasopharyngitis | 5 (31) | 0 | 5 (31) |
| Abdominal pain | 4 (25) | 0 | 4 (25) |
| Anemia | 2 (13) | 2 (13) | 4 (25) |
| Dyspnea | 2 (13) | 2 (13) | 4 (25) |
| Lower respiratory tract infection | 3 (19) | 1 (6) | 4 (25) |
| Productive cough | 4 (25) | 0 | 4 (25) |
| Rhinitis | 4 (25) | 0 | 4 (25) |
| Vomiting | 4 (25) | 0 | 4 (25) |
| Arthralgia | 3 (19) | 0 | 3 (19) |
| Asthenia | 3 (19) | 0 | 3 (19) |
| Conjunctivitis | 3 (19) | 0 | 3 (19) |
| Lymphopenia | 3 (19) | 0 | 3 (19) |
| Nausea | 3 (19) | 0 | 3 (19) |
| Petechiae | 3 (19) | 0 | 3 (19) |
| Purpura | 3 (19) | 0 | 3 (19) |
| Rales | 3 (19) | 0 | 3 (19) |
| Rash, maculopapular | 2 (13) | 1 (6) | 3 (19) |
| Upper respiratory tract infection | 2 (13) | 1 (6) | 3 (19) |
AE adverse event, MCL mantle cell lymphoma, TEAE treatment-emergent AE